Birgitte Volck


Birgitte is a senior executive and industry R&D leader who brings outstanding experience in rare disease research and development and commercialization, with a focus on innovative therapeutic modalities including gene therapy. She previously served as senior vice president and head of rare diseases R&D and medical affairs at GSK in the UK, where she oversaw an innovative rare diseases portfolio including ex vivo gene therapy programs for orphan disease indications. Prior to GSK, Birgitte was chief medical officer and SVP, head of development at Swedish Orphan Biovitrum (SOBI), leading the development of their portfolio in rare diseases including hemophilia, inflammation, neonatology and genetic metabolic diseases. In addition, Birgitte has held senior R&D and medical affairs positions with Genzyme, Pharmexa and Amgen, where she led early and late stage programs and worked with product commercialization from pre-approval to launch and lifecycle management. Birgitte serves on the advisory board of World Orphan Drug Congress and as non-executive director at Ascendis Pharma and Soleno Therapeutics. In the past, she has served on the boards of Wilson Therapeutics and Trial Form Support International CRO. She received her MD and PhD degrees from Copenhagen University, Denmark, where she is now an external lecturer.